Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

PURPOSE: The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with Myeloproliferative Neoplasms (MPNs). However, patients often lose response to ruxolitinib or suffer disease progression despite therapy with ruxolitinib. These observations have prompted efforts to devi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Rampal, Raajit K., Pinzon-Ortiz, Maria, Somasundara, Amritha Varshini Hanasoge, Durham, Benjamin, Koche, Richard, Spitzer, Barbara, Mowla, Shoron, Krishnan, Aishwarya, Li, Bing, An, Wenbin, Derkach, Andriy, Devlin, Sean, Rong, Xianhui, Longmire, Tyler, Eisman, Shira Esther, Cordner, Keith, Whitfield, Justin T., Vanasse, Gary, Cao, Alexander, Levine, Ross L.
Формат: Artigo
Язык:Inglês
Опубликовано: 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8197756/
https://ncbi.nlm.nih.gov/pubmed/33782031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4898
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы